miR-375通过编排药物基因表达来防止乙氨基引起的急性肝衰竭
Yi Wang1, Jinghua Liu2, Sha Zhu3
1Department of Pathophysiology, West China College of Basic Medical Sciences and Forensic Medicine, Sichuan University, Chengdu, Sichuan, P.R. China; Horae Gene Therapy Center, UMass Chan Medical School, Worcester, MA, USA.
概括
在小鼠中,microRNA-375 (miR-375) 显示出对过量服用乙氨基 (APAP) 引起的肝衰竭的强有力的保护. 这种微RNA调节基因表达,以增强排毒和谷氨合成,提供了一种新的治疗策略.
科学领域:
- 肝病学 肝病学是一种肝病学.
- 分子生物学分子生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 乙氨基 (APAP) 过量服用是急性肝衰竭 (ALF) 的主要原因之一.
- N-乙-p-基胺胺 (NAPQI) 中介于APAP的肝毒性.
- 目前的治疗N-乙半氨酸 (NAC) 的有效性可能是有限的;需要新的治疗方法.
研究的目的:
- 研究microRNA-375 (miR-375) 在APAP过量诱导ALF中的治疗潜力.
- 为了确定 miR-375 的保护作用背后的分子标和机制.
主要方法:
- 腺相关病毒血清型8 (AAV8) 用于在APAP过量治疗的小鼠模型中为肝脏特定的miR-375输送.
- 进行了肝转录组分析,以确定miR-375的点和受影响的途径.
- 关键酶和谷氨合成标记物的基因表达水平被量化.
主要成果:
- 通过AAV8输送子宫外miR-375显著保护于APAP诱导的ALF.
- 确定了Slc16a2,Cyb5b和Acsl5作为miR-375.5的直接目标.
- miR-375过度表达调高了Gstm3和GSS表达,同时降低了Cyp2e1.
- 通过AAV8介导的Gstm3表达赋予了保护,通过Cyp2e1破坏加强了保护.
结论:
- miR-375通过调节关键药物基因的表达来阻止APAP-ALF.
- miR-375增强了解毒路径和谷氨合成,这对于减轻APAP毒性至关重要.
- miR-375及其确定的点代表了治疗APAP诱导的肝损伤的有希望的治疗途径.
相关概念视频
Phase II Reactions: Glutathione Conjugation and Mercapturic Acid Formation
389
Glutathione, a tripeptide made up of glutamate, cysteine, and glycine, is a critical player in the detoxification of drugs and xenobiotics via a process known as glutathione conjugation or mercapturic acid formation. This phase II biotransformation reaction involves the covalent binding of glutathione to a drug or its metabolite, enhancing the compound's water solubility and enabling its excretion.
Several distinctive characteristics distinguish glutathione conjugation from other phase II...
Several distinctive characteristics distinguish glutathione conjugation from other phase II...
389
Hepatic Drug Excretion: Influencing Factors
234
The biliary system of the liver, crucial for bile secretion and drug excretion, comprises intrahepatic bile ducts that merge to form the common hepatic duct. This duct, carrying hepatic bile, combines with the cystic duct, draining the gallbladder and forming the common bile duct, which empties into the duodenum. Bile, produced by hepatic cells lining the bile canaliculi, is composed primarily of water, bile salts, pigments, electrolytes, and lesser amounts of cholesterol and fatty acids. Bile...
234
Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance
86
Drug transporters are critical in drug absorption, distribution, and excretion processes. They should be included in physiological-based pharmacokinetic (PBPK) models, which help predict human drug disposition. However, predicting this is challenging during drug development, especially when liver transport is involved. However, with a realistic representation of body transport processes, an accurate model may be possible.
A recent model describes pravastatin's hepatobiliary excretion,...
A recent model describes pravastatin's hepatobiliary excretion,...
86
Phase II Reactions: Acetylation Reactions
373
Acetylation, a phase II biotransformation reaction, introduces an acetyl group to drugs or their metabolites. Acetyltransferase enzymes facilitate this reaction, which resembles α-amino acid conjugation due to the addition of a functional group to the drug molecule.
The substrates for acetylation are typically drugs or their metabolites with an amino, sulfonamide, or hydrazine functional group. Acetylation can occur at several points in the drug molecule, including primary, secondary, and...
The substrates for acetylation are typically drugs or their metabolites with an amino, sulfonamide, or hydrazine functional group. Acetylation can occur at several points in the drug molecule, including primary, secondary, and...
373


